MetaADEDB 2.0 @ LMMD
Goserelin
(IKDXDQDKCZPQSZ-JHYYTBFNSA-N)
Structure
SMILES
CC(=O)O.OC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)NNC(=O)N)CCCN=C(N)N)CC(C)C)COC(C)(C)C)Cc1ccc(cc1)O)NC(=O)[C@H](Cc1c[nH]c2c1cccc2)NC(=O)[C@@H](NC(=O)[C@@H]1CCC(=O)N1)Cc1[nH]cnc1
Molecular Formula:
C61H88N18O16
Molecular Weight:
1329.460
Log P:
2.8709
Hydrogen Bond Acceptor:
32
Hydrogen Bond Donor:
18
TPSA:
533.19
CAS Number(s):
145781-92-6
Synonym(s)
1.
Goserelin
2.
Goserelin Acetate
3.
ICI-118630
4.
Zoladex
5.
Acetate, Goserelin
6.
ICI 118630
7.
ICI118630
External Link(s)
MeSHD017273
PubChem Compound16052011
BindingDB50247974
CHEMBLCHEMBL1200501
KEGGdr:D00573
Adverse Drug Event(s)
NameNumber of ReportsReference(s)Data Source
1Acute myocardial infarctionFAERS: 1US FAERS
2AngioedemaFAERS: 1US FAERS
3Device malfunctionFAERS: 1US FAERS
4Disease recurrenceFAERS: 1US FAERS
5HypersensitivityFAERS: 1US FAERS
6Neutrophil count decreasedFAERS: 1US FAERS
7Poor quality sleepFAERS: 1US FAERS
8Schizoaffective DisorderFAERS: 1US FAERS
9Troponin increasedFAERS: 1US FAERS
10AlopeciaCanada Vigilance: 1Canada Vigilance
11AstheniaCanada Vigilance: 1Canada Vigilance
12CellulitisCanada Vigilance: 1Canada Vigilance
13Disease ProgressionCanada Vigilance: 2Canada Vigilance
14General physical health deteriorationCanada Vigilance: 1Canada Vigilance
15LethargyCanada Vigilance: 1Canada Vigilance
16Malignant neoplasm progressionCanada Vigilance: 1Canada Vigilance
17Myocardial InfarctionCanada Vigilance: 1Canada Vigilance
18Pathological fractureCanada Vigilance: 1Canada Vigilance
19Pulmonary thrombosisCanada Vigilance: 1Canada Vigilance
20SciaticaCanada Vigilance: 1Canada Vigilance
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120241

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.